Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03321617 · ClinicalTrials.gov registry record · Phase 1
Glutamate Reducing Interventions in Schizophrenia
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03321617 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 16 participants.
The verdict
NCT03321617, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to determine whether these doses of POMA are affecting glutamate levels.
Interventions
- DRUG Pomaglumetad methionil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2020-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03321617
The ClinicalTrials.gov registry entry for NCT03321617 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pomaglumetad methionil is the first listed.
NCT03321617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03321617 about?
NCT03321617 is a clinical study titled "Glutamate Reducing Interventions in Schizophrenia". Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to determine whether these doses of POMA are affecting glutamate levels.
What is the current status of trial NCT03321617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-04-17. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT03321617?
The interventions under investigation include: Pomaglumetad methionil (DRUG).
Who is sponsoring clinical trial NCT03321617?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.